1. 1) Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol., 44, 1488–1496 (2004).
2. 2) Lewis GD, Semigran MJ. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr. Heart Fail. Rep., 1, 183–189 (2004).
3. 3) Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol., 53 (Suppl. 1), 5S–12S (2002).
4. 4) Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol., 61, 280–288 (2006).
5. 5) Shlobin OA, Brown AW, Weir N, Ahmad S, Lemma M, Nathan SD. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. Lung, 190, 573–578 (2012).